Table 2.
Ongoing combination studies involving nivolumab.
| Combination | Combination Partner | Trial Phase | ClinicalTrials.gov identifier |
|---|---|---|---|
| N versus N + ipilimumab versus ipilimumab | Anti-CTLA4 | III | NCT01844505 |
| N + ipilimumab versus ipilimumab | Anti-CTLA4 | II | NCT01927419 |
| N + ipiliumab | Anti-CTLA4 | I (biomarker) | NCT01621490 |
| N + lirilumab | Anti-KIR | I (solid tumors) | NCT01714739 |
| N + BMS-986016 | Anti-LAG-3 | I (solid tumors) | NCT01968109 |
| N + BMS-982470 | IL-21 | I (solid tumors) | NCT01629758 |
| N + ipilimumab | Anti-CTLA4 | Expanded access | NCT02186249 |
KIR, killer cell Ig-like receptors; LAG-3, lymphocyte-activation gene 3; IL, interleukin; N, nivolumab.